Posts

With ADA 2026 data in the books, analysts say Lilly is widening its lead in the obesity race

on

Lilly and Novo Face Off at ADA 2026 as Others Seek to Compete in Obesity

on

Lilly's triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile

on

Lilly's Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Diabetes Trial, Comparable to Mounjaro

on

Lilly's Triple-G Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Type 2 Diabetes Trial

on

Eli Lilly Commits $3.5 Billion to Build Injectable Obesity Drug Plant in Pennsylvania

on

Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported

on